Titre : Neurofibromine-1

Neurofibromine-1 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Muscle Strength Dynamometer
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Neurofibromine-1 : Questions médicales les plus fréquentes", "headline": "Neurofibromine-1 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Neurofibromine-1 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-16", "dateModified": "2025-03-11", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Neurofibromine-1" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines suppresseurs de tumeurs", "url": "https://questionsmedicales.fr/mesh/D025521", "about": { "@type": "MedicalCondition", "name": "Protéines suppresseurs de tumeurs", "code": { "@type": "MedicalCode", "code": "D025521", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.624.776" } } }, "about": { "@type": "MedicalCondition", "name": "Neurofibromine-1", "alternateName": "Neurofibromin 1", "code": { "@type": "MedicalCode", "code": "D025542", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Valentina Botero", "url": "https://questionsmedicales.fr/author/Valentina%20Botero", "affiliation": { "@type": "Organization", "name": "Department of Neuroscience and Pharmacology, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States of America." } }, { "@type": "Person", "name": "Hélène Bénédetti", "url": "https://questionsmedicales.fr/author/H%C3%A9l%C3%A8ne%20B%C3%A9n%C3%A9detti", "affiliation": { "@type": "Organization", "name": "Centre de Biophysique Moléculaire, CNRS, UPR 4301, University of Orléans and INSERM, CEDEX 2, 45071 Orléans, France." } }, { "@type": "Person", "name": "Matthew Drew", "url": "https://questionsmedicales.fr/author/Matthew%20Drew", "affiliation": { "@type": "Organization", "name": "NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21701, USA." } }, { "@type": "Person", "name": "Dominic Esposito", "url": "https://questionsmedicales.fr/author/Dominic%20Esposito", "affiliation": { "@type": "Organization", "name": "NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21701, USA." } }, { "@type": "Person", "name": "Dwight V Nissley", "url": "https://questionsmedicales.fr/author/Dwight%20V%20Nissley", "affiliation": { "@type": "Organization", "name": "NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21701, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Development and validation of a portable articulated dynamometry system to assess knee extensor muscle strength.", "datePublished": "2023-07-23", "url": "https://questionsmedicales.fr/article/37482569", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-023-39062-0" } }, { "@type": "ScholarlyArticle", "name": "Validity and reliability of handgrip dynamometry in older adults: A comparison of two widely used dynamometers.", "datePublished": "2022-06-21", "url": "https://questionsmedicales.fr/article/35727792", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0270132" } }, { "@type": "ScholarlyArticle", "name": "The Single Leg Bridge Test does not replace handheld dynamometer hamstring tests in a clinical setting.", "datePublished": "2023-08-06", "url": "https://questionsmedicales.fr/article/37573852", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ptsp.2023.08.001" } }, { "@type": "ScholarlyArticle", "name": "Concurrent Validity of Lower Limb Muscle Strength by Handheld Dynamometry in Children 7 to 11 Years Old.", "datePublished": "2022-08-22", "url": "https://questionsmedicales.fr/article/35995423", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1123/jsr.2021-0273" } }, { "@type": "ScholarlyArticle", "name": "Reliability of a new stabilization device for measurement of muscle strength using a hand-held dynamometer.", "datePublished": "2024-10-05", "url": "https://questionsmedicales.fr/article/39367722", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/mus.28266" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines tumorales", "item": "https://questionsmedicales.fr/mesh/D009363" }, { "@type": "ListItem", "position": 5, "name": "Protéines suppresseurs de tumeurs", "item": "https://questionsmedicales.fr/mesh/D025521" }, { "@type": "ListItem", "position": 6, "name": "Neurofibromine-1", "item": "https://questionsmedicales.fr/mesh/D025542" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Neurofibromine-1 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Neurofibromine-1", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-13", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Neurofibromine-1", "description": "Comment diagnostiquer la neurofibromatose de type 1 ?\nQuels tests génétiques sont utilisés ?\nQuels signes cliniques sont observés ?\nLes IRM sont-elles utiles pour le diagnostic ?\nQuel rôle joue l'historique familial ?", "url": "https://questionsmedicales.fr/mesh/D025542?mesh_terms=Muscle+Strength+Dynamometer&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Neurofibromine-1", "description": "Quels sont les symptômes courants de la neurofibromatose ?\nLes troubles cognitifs sont-ils fréquents ?\nY a-t-il des complications oculaires ?\nComment les douleurs sont-elles ressenties ?\nLes symptômes varient-ils d'une personne à l'autre ?", "url": "https://questionsmedicales.fr/mesh/D025542?mesh_terms=Muscle+Strength+Dynamometer&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Neurofibromine-1", "description": "Peut-on prévenir la neurofibromatose de type 1 ?\nLe dépistage précoce est-il recommandé ?\nY a-t-il des conseils pour les familles à risque ?\nLes tests génétiques sont-ils utiles pour la prévention ?\nComment sensibiliser à la maladie ?", "url": "https://questionsmedicales.fr/mesh/D025542?mesh_terms=Muscle+Strength+Dynamometer&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Neurofibromine-1", "description": "Quels traitements sont disponibles pour la neurofibromatose ?\nLa chirurgie est-elle toujours nécessaire ?\nDes médicaments sont-ils prescrits ?\nY a-t-il des thérapies ciblées ?\nComment se déroule le suivi médical ?", "url": "https://questionsmedicales.fr/mesh/D025542?mesh_terms=Muscle+Strength+Dynamometer&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Neurofibromine-1", "description": "Quelles sont les complications possibles ?\nLes complications peuvent-elles affecter la qualité de vie ?\nY a-t-il des risques de cancer associés ?\nComment gérer les complications ?\nLes complications sont-elles prévisibles ?", "url": "https://questionsmedicales.fr/mesh/D025542?mesh_terms=Muscle+Strength+Dynamometer&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Neurofibromine-1", "description": "Quels sont les facteurs de risque de la neurofibromatose ?\nLa neurofibromatose est-elle héréditaire ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLes mutations génétiques sont-elles fréquentes ?\nY a-t-il des groupes à risque particulier ?", "url": "https://questionsmedicales.fr/mesh/D025542?mesh_terms=Muscle+Strength+Dynamometer&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer la neurofibromatose de type 1 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen clinique et l'identification de critères spécifiques." } }, { "@type": "Question", "name": "Quels tests génétiques sont utilisés ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques peuvent identifier des mutations dans le gène NF1." } }, { "@type": "Question", "name": "Quels signes cliniques sont observés ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent des neurofibromes, des taches café au lait et des frecklings." } }, { "@type": "Question", "name": "Les IRM sont-elles utiles pour le diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les IRM peuvent détecter des tumeurs et des anomalies nerveuses." } }, { "@type": "Question", "name": "Quel rôle joue l'historique familial ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Un historique familial de neurofibromatose peut renforcer le diagnostic." } }, { "@type": "Question", "name": "Quels sont les symptômes courants de la neurofibromatose ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des neurofibromes, des taches cutanées et des douleurs." } }, { "@type": "Question", "name": "Les troubles cognitifs sont-ils fréquents ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles d'apprentissage et des difficultés cognitives peuvent survenir." } }, { "@type": "Question", "name": "Y a-t-il des complications oculaires ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des tumeurs de la rétine peuvent se produire." } }, { "@type": "Question", "name": "Comment les douleurs sont-elles ressenties ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les douleurs peuvent être localisées autour des neurofibromes ou diffuses." } }, { "@type": "Question", "name": "Les symptômes varient-ils d'une personne à l'autre ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'expression des symptômes peut varier considérablement entre les individus." } }, { "@type": "Question", "name": "Peut-on prévenir la neurofibromatose de type 1 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de méthode de prévention pour cette maladie génétique." } }, { "@type": "Question", "name": "Le dépistage précoce est-il recommandé ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Le dépistage précoce peut aider à identifier les symptômes et à initier le suivi." } }, { "@type": "Question", "name": "Y a-t-il des conseils pour les familles à risque ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les familles à risque devraient consulter un généticien pour des conseils adaptés." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils utiles pour la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent aider à identifier les porteurs de mutations." } }, { "@type": "Question", "name": "Comment sensibiliser à la maladie ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "La sensibilisation peut se faire par des campagnes d'information et des ressources éducatives." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour la neurofibromatose ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la surveillance, la chirurgie et la gestion des symptômes." } }, { "@type": "Question", "name": "La chirurgie est-elle toujours nécessaire ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Non, la chirurgie est réservée aux cas où les neurofibromes causent des problèmes." } }, { "@type": "Question", "name": "Des médicaments sont-ils prescrits ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments peuvent être utilisés pour gérer la douleur et d'autres symptômes." } }, { "@type": "Question", "name": "Y a-t-il des thérapies ciblées ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches sont en cours sur des thérapies ciblées pour la neurofibromatose." } }, { "@type": "Question", "name": "Comment se déroule le suivi médical ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Le suivi médical régulier est essentiel pour surveiller l'évolution de la maladie." } }, { "@type": "Question", "name": "Quelles sont les complications possibles ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des tumeurs malignes, des problèmes neurologiques et des douleurs." } }, { "@type": "Question", "name": "Les complications peuvent-elles affecter la qualité de vie ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement impacter la qualité de vie des patients." } }, { "@type": "Question", "name": "Y a-t-il des risques de cancer associés ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients ont un risque accru de développer certains types de cancer." } }, { "@type": "Question", "name": "Comment gérer les complications ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite une approche multidisciplinaire et un suivi régulier." } }, { "@type": "Question", "name": "Les complications sont-elles prévisibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être prévisibles, mais leur apparition varie selon les individus." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque de la neurofibromatose ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux et des mutations génétiques spécifiques." } }, { "@type": "Question", "name": "La neurofibromatose est-elle héréditaire ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la neurofibromatose de type 1 est généralement héréditaire et autosomique dominante." } }, { "@type": "Question", "name": "Les facteurs environnementaux jouent-ils un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, les facteurs environnementaux ne sont pas clairement établis comme des risques." } }, { "@type": "Question", "name": "Les mutations génétiques sont-elles fréquentes ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les mutations dans le gène NF1 sont fréquentes chez les personnes atteintes." } }, { "@type": "Question", "name": "Y a-t-il des groupes à risque particulier ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Les individus ayant des antécédents familiaux sont à risque accru de développer la maladie." } } ] } ] }

Sources (10000 au total)

Validity and reliability of handgrip dynamometry in older adults: A comparison of two widely used dynamometers.

Among older adults, decreased handgrip strength is associated with greater risk of frailty, and loss of physical function, mobility, lean mass, and overall muscular strength and power. Frailty is also... Sixty-seven older (76.2 ± 0.9 years) men (n = 34) and women (n = 33) completed two trials of handgrip strength measurement on sequential days (T1, T2) using both devices in random order. Intraclass co... There were significant (p < 0.001) relationships between devices at T1 (r = 0.94) and T2 (r = 0.94) and strong (p < 0.001) intraclass correlations were observed for both devices (Jamar = 0.98; Smedley... Our results demonstrate that despite excellent reliability, there is poor agreement between devices, indicating a lack of validity. For use as a diagnostic tool, standardization and device-specific cu...

The Single Leg Bridge Test does not replace handheld dynamometer hamstring tests in a clinical setting.

To examine the correlation of Single Leg Bridge Test (SLBT) scores with maximum isometric strength values obtained in handheld dynamometer (HHD) hamstring tests performed in a clinical setting.... Cross-sectional study.... Physical therapy clinic.... Fifty healthy and physically active men.... Correlation between SLBT scores and force values found in three HHD hamstring tests: test 'A', volunteer in prone with hip in neutral position and the knee flexed at ∼90°; test 'B', volunteer in supin... The volunteers' SLBT score was 27.55 ± 7.81 repetitions. The SLBT scores were poorly associated with mean (r = 0.246) and peak (r = 0.321) results provided by HHD test 'A'. There were no significant c... HHD hamstring tests should not be replaced by the SLBT. We recommend for clinicians to applying such tests in a complementary way to assess the hamstring's functional status....

Concurrent Validity of Lower Limb Muscle Strength by Handheld Dynamometry in Children 7 to 11 Years Old.

The assessment of pediatric muscle strength is necessary in a range of applications, including rehabilitation programs. Handheld dynamometry (HHD) is considered easy to use, portable, and low cost, bu... To determine the concurrent validity of lower limb torque from HHD compared with isokinetic dynamometry (ID) in children aged from 7 to 11 years old.... A descriptive assessment of concurrent validity of lower limb joint torques from HHD compared with ID.... Sixty-one typically developing children underwent assessment of maximal hip, knee, and ankle isometric torque by HHD and ID using standardized protocols. Joint positions were selected to represent max... Correlations between HHD and ID were moderate to large for knee extension (r 95% CI, .39 to .73), small to large for plantar flexion (r 95% CI, .29 to .67), knee flexion (r 95% CI, .16 to .59), hip fl... Maximal torque values from HHD and ID are consistent with those previously reported in the literature. Poor concurrent validity of HHD may have arisen from issues around joint position, joint stabiliz...

Reliability of a new stabilization device for measurement of muscle strength using a hand-held dynamometer.

The hand-held dynamometer (HHD) is a reliable and portable tool for quantitatively assessing muscle strength. However, a number of variables, including the strength of the tester, the adequacy of stab... Strength assessments were conducted with and without the stabilization device by two independent raters. Healthy volunteers with no history of musculoskeletal disorders were included in the study. The... Fifty-two healthy volunteers (age 21.51 ± 2.02 years) participated in the study. The reproducibility was found to be excellent (ICC = 0.89-0.99). While reliability between the assessors was good to ex... The strength values obtained for all directions of movement with the stabilization device were found to be significantly higher than those obtained without fixation of the HHD. It can be concluded tha...

A Novel Intrinsic Foot Muscle Strength Dynamometer Demonstrates Moderate-To-Excellent Reliability and Validity.

Intrinsic foot muscle (IFM) weakness can result in reduced foot function, making it crucial for clinicians to track IFM strength changes accurately. However, assessing IFM strength can be challenging ... The purpose was to investigate the intra-rater and inter-rater reliability of a novel, budget-friendly IFM dynamometer and determine its agreement with a handheld dynamometer (HHD). The researchers al... Descriptive Laboratory Study.... Two assessors measured IFM strength of 34 healthy volunteers (4 male, 30 female; age=21.14±2.57, height=164.66 ±7.62 cm, mass=64.45±11.93 kg) on two occasions 6.62±0.78 days apart with the novel dynam... For the novel dynamometer, intra- and inter-rater reliability was moderate-to-excellent (ICC = 0.73 - 0.95), and the majority of the strength tests were within the 95% limits of agreement with the HHD... This novel IFM dynamometer is a budget-friendly ($75) tool that was shown to be reliable and valid in a healthy population.... Level 3©The Author(s)....

Intra- and inter-rater reliability, agreement, and minimal detectable change of the handheld dynamometer in individuals with symptomatic hip osteoarthritis.

The handheld dynamometer has been validated to measure muscle strength in different muscle groups. However, to date, it has not been tested in individuals who experience pain induced by hip osteoarthr... Twenty participants with hip osteoarthritis (mean ± SD age: 58.7±15.3 years; body mass index: 28.8±4.2 kg/m2) and pain intensity on the Visual Analogue Scale ≥ 4 (8.05±1.2) were recruited to participa... The intra-rater intraclass correlation coefficient (ICC) was classified as good (>0.75) or excellent (≥0.90) for all muscle groups and all inter-rater ICCs were classified as excellent. Rater A had a ... Despite pain and dysfunction related to hip osteoarthritis, the mean of two measures using a handheld dynamometer was shown to be a reliable tool to assess hip muscle strength, with good to excellent ...

Reliability and validity of two hand dynamometers when used by community-dwelling adults aged over 50 years.

The Jamar hydraulic dynamometer is a widely recognized tool for measuring grip strength. Nevertheless, the devices used most often in Asian countries are spring-type dynamometers, represented by the C... This was a cross-sectional study using a random crossover design in the grip strength test with two dynamometers. A total of 1064 healthy community-dwelling older adults aged 50-90 years old, which in... The average handgrip strength (HGS) values at six times by the Jamar and CAMRY devices were 25.0 ± 7.9 kg and 24.6 ± 7.5 kg, respectively. The ICC values between the two devices were 0.815-0.854, and ... The CAMRY EH101 dynamometer provides excellent reliability and validity. This device can serve as a reliable, inexpensive, and practical device to assess grip strength in geriatric clinical practice.... Chinese Clinical Trial Registry: ChiCTR2100046367 ; Date of clinical trial reistration: 15/05/2021....

Psychometric properties of a standardized protocol of muscle strength assessment by hand-held dynamometry in healthy adults: a reliability study.

Maximal isometric muscle strength (MIMS) assessment is a key component of physiotherapists' work. Hand-held dynamometry (HHD) is a simple and quick method to obtain quantified MIMS values that have be... To determine the intra- and inter-rater reliability, standard error of measurement (SEM) and minimal detectable change (MDC) of MIMS torque values obtained with HHD.... Intra and Inter-rater Reliability Study. The MIMS torque of 17 muscle groups was assessed by two independent raters at three different times in 30 healthy adults using a standardized HHD protocol usin... Intra- and inter-rater reliability were excellent with ICC (95% confidence interval) varying from 0.90 to 0.99 (0.85-0.99) and 0.89 to 0.99 (0.55-0.995), respectively. Absolute SEM and MDC for intra-r... The excellent reliability obtained in this study suggest that the use of such a standardized HHD protocol is a method of choice for MIMS torque measurements in both clinical and research settings. And...